| [1] |
Burstein HJ, Curigliano G, Loibl S, et al. Estimating the benefits of therapy for early-stage breast cancer: the St Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019[J]. Ann Oncol，2019，30(10): 1541-1557.
|
| [2] |
von Minckwitz G, Kummel S, Vogel P, et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase Ⅲ randomized GeparTrio trial[J]. J Natl Cancer Inst，2008，100(8): 542-551.
|
| [3] |
Bear HD, Anderson S, Smith RE, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer：National Surgical Adjuvant Breast and Bowel Project Protocol B-27[J]. J Clin Oncol，2006，24(13): 2019-2027.
|
| [4] |
Steger GG, Galid A, Gnant M, et al. Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14[J]. J Clin Oncol，2007，25(15): 2012-2018.
|
| [5] |
Sanford RA, Lei X, Barcenas CH, et al. Impact of time from completion of neoadjuvant chemotherapy to surgery on survival outcomes in breast cancer patients[J]. Ann Surg Oncol，2016，23(5): 1515-1521.
|
| [6] |
Omarini C, Guaitoli G, Noventa S, et al. Impact of time to surgery after neoadjuvant chemotherapy in operable breast cancer patients[J]. Eur J Surg Oncol，2017，43(4): 613-618.
|
| [7] |
Golshan M, Cirrincione CT, Sikov WM, et al. Impact of neoadjuvant chemotherapy in stage Ⅱ-Ⅲ triple negative breast cancer on eligibility for breast-conserving surgery and breast conservation rates: surgical results from CALGB 40603 (Alliance)[J]. Ann Surg，2015，262(3): 434-439.
|
| [8] |
Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Clin Oncol，1997，15(7): 2483-2493.
|
| [9] |
Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy[J]. Clin Cancer Res，2005，11(24 Pt 1): 8715-8721.
|
| [10] |
Mieog JS, van der Hage JA, van de Velde CJ. Neoadjuvant chemotherapy for operable breast cancer[J]. Br J Surg，2007，94(10): 1189-1200.
|
| [11] |
Wolmark N, Wang J, Mamounas E, et al. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18[J]. J Natl Cancer Inst Monogr，2001，(30): 96-102.
|
| [12] |
Asselain B, Barlow W, Bartlett J, et al. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials[J]. Lancet Oncol，2018，19(1): 27-39.
|
| [13] |
von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes[J]. J Clin Oncol，2012，30(15): 1796-1804.
|
| [14] |
Huang EH, Strom EA, Perkins GH, et al. Comparison of risk of local-regional recurrence after mastectomy or breast conservation therapy for patients treated with neoadjuvant chemotherapy and radiation stratified according to a prognostic index score[J]. Int J Radiat Oncol Biol Phys，2006，66(2): 352-357.
|
| [15] |
张嘉庆，程琳，郭嘉嘉. 乳腺癌外科治疗中一些争议问题的探讨[J/CD]. 中华乳腺病杂志(电子版)，2010，4(2): 121-128.
|
| [16] |
Ishitobi M, Ohsumi S, Inaji H, et al. Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index[J]. Cancer，2012，118(18): 4385-4393.
|
| [17] |
Curigliano G, Burstein HJ, Winer EP, et al. De-escalating and escalating treatments for early-stage breast cancer: the St Gallen International Expert Consensus Conference on the primary therapy of early breast cancer 2017[J]. Ann Oncol，2017，28(8): 1700-1712.
|
| [18] |
Houssami N, Macaskill P, Marinovich ML, et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis[J]. Ann Surg Oncol，2014，21(3): 717-730.
|
| [19] |
Chirag Shah VV, Sayles H, Rechi A, et al. Abstract GS5-01: Appropriate margins for breast conserving surgery in patients with early stage breast cancer: a meta-analysis[J]. Cancer Res，2018，78(4 Suppl): GS5-01.
|
| [20] |
Daveau C, Savignoni A, Abrous-Anane S, et al. Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy？[J]. Int J Radiat Oncol Biol Phys，2011，79(5): 1452-1459.
|
| [21] |
Ring A, Webb A, Ashley S, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer？[J]. J Clin Oncol，2003，21(24): 4540-4545.
|
| [22] |
van la Parra RF, Kuerer HM. Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials[J]. Breast Cancer Res，2016，18(1): 28.
|
| [23] |
Kuerer HM, Rauch GM, Krishnamurthy S, et al. A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy[J]. Ann Surg，2018，267(5): 946-951.
|
| [24] |
Kuerer H. Eliminating breast cancer surgery in exceptional responders with neoadjuvant systemic therapy[EB/OL]. [2019-12-10].
URL
|
| [25] |
Heil J. Diagnosis of pathological complete response by vacuum-assisted biopsy after neoadjuvant chemotherapy in breast cancer (RESPONDER) [EB/OL]．[2019-12-10].
URL
|
| [26] |
Hunt KK, Yi M, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients[J]. Ann Surg，2009，250(4): 558-566.
|
| [27] |
Geng C, Chen X, Pan X, et al. The feasibility and accuracy of sentinel lymph node biopsy in initially clinically node-negative breast cancer after neoadjuvant chemotherapy: A systematic review and meta-analysis[J]. PLoS One，2016，11(9): e162605.
|
| [28] |
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study[J]. Lancet Oncol，2013，14(7): 609-618.
|
| [29] |
Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0-T4, N1-N2) Who receive neoadjuvant chemotherapy: Results from ACOSOG Z1071 (Alliance)[J]. Ann Surg，2016，263(4): 802-807.
|
| [30] |
Boileau JF, Poirier B, Basik M, et al. Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study[J]. J Clin Oncol，2015，33(3): 258-264.
|
| [31] |
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27[J]. J Clin Oncol，2008，26(5): 778-785.
|
| [32] |
Dominici LS, Negron GV, Buzdar AU, et al. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer[J]. Cancer，2010，116(12): 2884-2889.
|
| [33] |
Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases：Results of a prospective study[J]. Ann Surg Oncol，2016，23(11): 3467-3474.
|
| [34] |
Wong SM, Weiss A, Mittendorf EA, et al. Surgical management of the axilla in clinically node-positive patients receiving neoadjuvant chemotherapy: A national cancer database analysis[J]. Ann Surg Oncol，2019，26(11): 3517-3525.
|
| [35] |
Galimberti V, Ribeiro FS, Maisonneuve P, et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment[J]. Eur J Surg Oncol，2016，42(3): 361-368.
|
| [36] |
Kang YJ, Han W, Park S, et al. Outcome following sentinel lymph node biopsy-guided decisions in breast cancer patients with conversion from positive to negative axillary lymph nodes after neoadjuvant chemotherapy[J]. Breast Cancer Res Treat，2017，166(2): 473-480.
|
| [37] |
Martelli G, Miceli R, Folli S, et al. Sentinel node biopsy after primary chemotherapy in cT2 N0/1 breast cancer patients: Long-term results of a retrospective study[J]. Eur J Surg Oncol，2017，43(11): 2012-2020.
|
| [38] |
中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J]. 中国癌症杂志，2019，29(8): 609-680.
|
| [39] |
邵志敏，江泽飞，李俊杰，等．中国乳腺癌新辅助治疗专家共识(2019年版)[J]. 中国癌症杂志，2019，29(5): 390-400.
|
| [40] |
Boughey J. Comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast cancer treated with chemotherapy[EB/OL]. [2019-12-10].
URL
|
| [41] |
Wolmark N. Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery[EB/OL]. [2019-12-10].
URL
|